Skip to content

This site is intended for UK healthcare professionals only. If you are not a UK healthcare professional, please visit our dedicated site for more information at www.beigene.co.uk

BRUKINSA logo

NICE recommends BRUKINSA as an option for treating adult patients with MZL who have had at least one anti‑CD20-based treatment.1

It is only recommended if the company provides it according to the commercial arrangement.1

BRUKINSA monotherapy is accepted by SMC as an option for the treatment of adult patients with MZL who have received at least one prior anti-CD20-based therapy.2

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.2

BRUKINSA achieved deep and sustained responses in patients with R/R MZL3

Marginal zone lymphoma

Primary endpoint: IRC-assessed ORR

Median follow-up: 28.0 months

Adapted from Opat, et al. 2023.3

ORR by MZL subtype

Extranodal

64%

CR 40%

(n=25)

Nodal

76%

CR 20%

(n=25)

Splenic

67%

CR 8%

(n=12)

Median time to response

2.8 Months

Secondary endpoint: Investigator-assessed PFS

Median follow-up: 27.4 months

Adapted from Opat, et al. 2023.3

Scroll left and right to see more

Rate of atrial fibrillation or flutter

Any-grade:

2.9%

(n=2/68)

Grade ≥3:

1.5%

(n=1/68)

Dose reduction rate due to AEs

0%

(n=0/68)

Discontinuation rate due to AEs

7%

(n=5/68)

Median duration of treatment: 24.2 months

document
READ ABOUT THE MAGNOLIA STUDY
chevron
Learn more about BRUKINSA:
Select an indication to learn more about BRUKINSA: